To assess whether CARD14 variants could be associated with better responses in psoriasis patients to anti-TNF therapy, Coto-Segura and colleagues tested the presence of such variants in 116 patients who underwent anti-TNF treatment (48). This evidence concerns the gene TNF and psoriasis.